ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down [Yahoo! Finance]
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Yahoo! Finance
its new drug application (NDA) for oral sulopenem for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women. The FDA held the AMDAC meeting on Sept. 9, to discuss the overall benefits and risks of oral sulopenem in treating uUTIs in women aged more than 18 years and important factors for medical providers to know to ensure the proper use of sulopenem. The FDA did not urge the AMDAC to vote on any matter. Per some market reports, sulopenem's off-label use for treating uUTIs could be attached to a degree of high risk. There are chances that sulopenem will be approved with certain limitations. In such a scenario, a post-marketing study would be imperative to confirm sulopenem's proper use and label. This might have hurt investors' sentiments and resulted in the stock going down 12% on Sept. 10 following the announcement of the news. Shares of Iterum have plunged 51.8% so far this year compared with the industry's decrease of 0.8%. Image Source: Zack
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis [Yahoo! Finance]Yahoo! Finance
- Illumina and LGC Biosearch Technologies join forces to drive genomic innovation in agriculturePR Newswire
- China's Failing US Lobby Playbook Puts Tech Companies at Risk [Yahoo! Finance Canada]Yahoo! Finance Canada
- FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer [Yahoo! Finance]Yahoo! Finance
- Bioinformatics Market to Reach $31.71 Billion by 2031, Driven by Growing Research Activities in Genomics and Rising Need to Develop Novel Drugs/Drug Molecules - Exclusive Report by Meticulous Research® [Yahoo! Finance]Yahoo! Finance
ILMN
Earnings
- 8/6/24 - Beat
ILMN
Sec Filings
- 9/17/24 - Form 4
- 9/9/24 - Form 4
- 9/9/24 - Form 8-K
- ILMN's page on the SEC website